Business Description
Corbus Pharmaceuticals Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US21833P3010
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 44.15 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.6 | |||||
3-Year EPS without NRI Growth Rate | 37.5 | |||||
3-Year FCF Growth Rate | 39.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 6.25 | |||||
9-Day RSI | 16.73 | |||||
14-Day RSI | 24.36 | |||||
6-1 Month Momentum % | -59.25 | |||||
12-1 Month Momentum % | 226.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 13.84 | |||||
Quick Ratio | 13.84 | |||||
Cash Ratio | 13.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | -107.36 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -52.81 | |||||
ROA % | -38.21 | |||||
ROIC % | -243.19 | |||||
ROC (Joel Greenblatt) % | -1198.04 | |||||
ROCE % | -57.4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.07 | |||||
Price-to-Tangible-Book | 1.11 | |||||
EV-to-EBIT | -0.1 | |||||
EV-to-Forward-EBIT | -0.06 | |||||
EV-to-EBITDA | -0.1 | |||||
EV-to-FCF | -0.12 | |||||
Price-to-Net-Current-Asset-Value | 1.13 | |||||
Price-to-Net-Cash | 1.14 | |||||
Earnings Yield (Greenblatt) % | -1000 | |||||
FCF Yield % | -22.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Ā
Total Annual Return % Ā
Corbus Pharmaceuticals Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -4.67 | ||
Beta | -0.4 | ||
Volatility % | 333.61 | ||
14-Day RSI | 24.36 | ||
14-Day ATR ($) | 0.867487 | ||
20-Day SMA ($) | 15.657145 | ||
12-1 Month Momentum % | 226.55 | ||
52-Week Range ($) | 5.3683 - 61.8144 | ||
Shares Outstanding (Mil) | 12.18 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Corbus Pharmaceuticals Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Corbus Pharmaceuticals Holdings Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc(LTS:0SZI)'s stock price today?
When is next earnings date of Corbus Pharmaceuticals Holdings Inc(LTS:0SZI)?
Does Corbus Pharmaceuticals Holdings Inc(LTS:0SZI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |